A PHASE II TRIAL OF DOXIL, RITUXIMAB, CYCLOPHOSPHAMIDE,

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 具体目标： 主要目标： 确定新诊断的艾滋病相关淋巴瘤患者对DR-COP的有效率(CR+CRU+PR)。 以确定接受DR-COP治疗的患者的有效时间(DR)(无复发存活率)。 以确定接受DR-COP治疗的患者的中位生存时间。 以确定接受DR-COP治疗的患者的细菌、真菌和机会性感染的比率。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: Primary Aims: " To determine the response rate (CR + CRu + PR) to DR-COP in patients with newly-diagnosed AIDS-related lymphoma. " To determine the duration of response (DR) (relapse-free survival) of patients treated with DR-COP. " To determine the median survival time of patients treated with DR-COP. " To determine rate of bacterial, fungal and opportunistic infections in patients treated with DR-COP.